An alternative strategy for HER2-low metastatic breast cancer with CD147 upregulation is combination therapy with trastuzumab and HuM6-1B9, which could provide a synergistic ADCC effect to enhance cancer cell elimination at a more affordable cost. The gene discussed is ERBB2; the disease is cancer.